Published in Front Oncol on September 29, 2017
Tempus Priority Study: A Pan-tumor Observational Study | NCT05179824
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Cancer genome landscapes. Science (2013) 25.33
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol (2014) 6.52
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15
The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell (1997) 4.11
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol (2012) 3.90
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol (1997) 2.99
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.80
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol (2004) 2.27
Discoidin domain receptors: structural relations and functional implications. FASEB J (1999) 2.23
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res (2016) 2.19
Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist (2013) 2.04
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist (2011) 2.02
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol (2015) 1.92
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res (2011) 1.73
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 1.67
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov (2015) 1.67
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2007) 1.65
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood (2000) 1.65
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 1.64
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol (2012) 1.61
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol (2015) 1.56
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol (2014) 1.53
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther (2014) 1.51
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res (2005) 1.31
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol (2016) 1.27
Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer (2013) 1.24
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2009) 1.22
Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol (2001) 1.20
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 1.17
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol (2012) 1.17
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol (2015) 1.12
ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology (2014) 1.10
Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta (2012) 1.09
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol (2016) 1.06
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res (2014) 1.05
Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res (1996) 1.05
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol (2016) 1.02
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol (2016) 1.01
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discov (2015) 0.98
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov (2016) 0.98
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2015) 0.97
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med (2016) 0.96
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol (2014) 0.96
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res (2014) 0.96
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol (2015) 0.96
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 0.95
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget (2015) 0.95
KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep (2012) 0.95
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer (2015) 0.94
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer (2015) 0.91
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin Investig Drugs (2016) 0.90
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. J Clin Oncol (2016) 0.88
Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des (2014) 0.86
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs (2015) 0.86
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol (2016) 0.86
RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med (2012) 0.85
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol (2016) 0.85
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer (2015) 0.83
Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget (2015) 0.83